Advaxis, Inc. (ADXS) Upgraded to Buy by BidaskClub
Advaxis, Inc. (NASDAQ:ADXS) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
A number of other research firms also recently issued reports on ADXS. ValuEngine raised Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a research report on Monday, June 12th. Finally, HC Wainwright set a $23.00 target price on Advaxis and gave the stock a “buy” rating in a research report on Wednesday, June 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $22.00.
Advaxis (NASDAQ ADXS) traded up 2.92% during mid-day trading on Friday, reaching $7.41. The company had a trading volume of 472,768 shares. Advaxis has a 12-month low of $5.70 and a 12-month high of $12.66. The stock has a 50-day moving average of $6.50 and a 200 day moving average of $7.54. The company’s market capitalization is $299.82 million.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Stevens Capital Management LP purchased a new position in shares of Advaxis in the first quarter valued at $105,000. Voya Investment Management LLC grew its position in shares of Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares in the last quarter. Cutler Capital Management LLC purchased a new position in shares of Advaxis in the second quarter valued at $130,000. American International Group Inc. grew its position in shares of Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 1,459 shares in the last quarter. Finally, Northern Capital Management LLC grew its position in shares of Advaxis by 14.6% in the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,650 shares in the last quarter. Institutional investors own 48.78% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.